{"ATC Code":"N02CC02","Abbreviation":"","Aliases":["naratriptanum","N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide","N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide","N-Methyl-2-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)ethanesulfonamide","N-methyl-2-(3-(1-methyl-4-piperidyl)-1H-indol-5-yl)-ethanesulfonamide","N02CC02","N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide","Naramig","1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)-","Colatan"],"Biological Half-Life":"5-8 hours","CAS":"121679-13-8","ChEBI":"CHEBI:7478","ChEMBL":"CHEMBL1278","ChemicalClasses":["piperidine"],"Chirality":"achiral","Classes":null,"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Serotonin Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Triptans; Vasoconstrictor Agents","Drug Indication":"For the acute treatment of migraine attacks with or without aura in adults.","DrugClasses":[],"EliminationHalfLife":"5 – 8 hours","European Community (EC) Number":"601-800-8","FDA Pharmacological Classification":"QX3KXL1ZA2","FullSalts":["Naratriptan hydrochloride"],"HMDB ID":"HMDB0015087","HeavyAtomCount":23,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Serotonin Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Triptans; Vasoconstrictor Agents","IUPACName":"N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide","InChI":"InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3","InChIKey":"AMKVXSZCKVJAGH-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)","Melting Point":"246 °C","MolecularFormula":"C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e25\u003c/sub\u003eN\u003csub\u003e3\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003eS","MolecularWeight":"335.5 g/mol","Pharmacodynamics":"Naratriptan is a selective agonist of serotonin (5-hydroxytryptamine; 5-HT) type 1B and 1D receptors. It is structurally and pharmacologically related to other selective 5-HT1B/1D receptor agonist. Naratriptan has only a weak affinity for 5-HT\u003csub\u003e1A\u003c/sub\u003e, 5-HT\u003csub\u003e5A\u003c/sub\u003e, and 5-HT\u003csub\u003e7\u003c/sub\u003e receptors and no significant affinity or pharmacological activity at 5-HT\u003csub\u003e2\u003c/sub\u003e, 5-HT\u003csub\u003e3\u003c/sub\u003e or 5-HT\u003csub\u003e4\u003c/sub\u003e receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Naratriptan also activates 5-HT\u003csub\u003e1\u003c/sub\u003e receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Naratriptan in humans.","Physical Description":"Solid","PrevSalts":["hydrochloride"],"PubChemId":4440,"Record Description":["Naratriptan is a sulfonamide, a member of tryptamines and a heteroarylpiperidine. It has a role as a serotonergic agonist and a vasoconstrictor agent.","Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.","Naratriptan is a Serotonin-1b and Serotonin-1d Receptor Agonist. The mechanism of action of naratriptan is as a Serotonin 1b Receptor Agonist, and Serotonin 1d Receptor Agonist.","NARATRIPTAN is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for migraine disorder and has 1 investigational indication.","Naratriptan is only found in individuals that have used or taken this drug. It is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist.Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.","See also: Naratriptan Hydrochloride (has salt form).","Naratriptan is a sulfonamide, a member of tryptamines and a heteroarylpiperidine. It has a role as a serotonergic agonist and a vasoconstrictor agent.","LiverTox|CNS|Migraine|5HT-1 receptor agonist"],"RefCount":3,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Naratriptan","Name":"Naratriptan","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q421315","Name":"Naratriptan","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00952","Name":"Naratriptan","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/4440","Name":"Naratriptan","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1278","Name":"Naratriptan","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7478","Name":"Naratriptan","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=121679-13-8","Name":"Naratriptan","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0015087","Name":"Naratriptan","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07792","Name":"Naratriptan","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/QX3KXL1ZA2","Name":"Naratriptan","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID7023354","Name":"Naratriptan","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 4440, Naratriptan. Accessed July 3, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/4440\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/4440\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Naratriptan. UNII: QX3KXL1ZA2. Global Substance Registration System. Accessed July 3, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/QX3KXL1ZA2\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/QX3KXL1ZA2\u003c/a\u003e"],"SMILES":"CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C","Salts":["hydrochloride"],"SaltsAcidCount":[1],"SaltsAmineCount":[1],"SaltsUNII":["10X8X4P12Z"],"Scheduling":[],"Solubility":"1.14e-01 g/L","StoreUNII":["QX3KXL1ZA2"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="117.737mm" version="1.2" viewBox="0 0 102.416 117.737" width="102.416mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="118.0" stroke="none" width="103.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="92.524" x2="94.819" y1=".974" y2="12.077"/>
                  
            <line class="bond" id="mol1bnd2" x1="92.622" x2="86.739" y1="18.557" y2="23.795"/>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="81.216" x2="77.25" y1="23.475" y2="17.048"/>
                        
                <line x1="83.291" x2="79.325" y1="22.195" y2="15.768"/>
                      
                <line class="hi" stroke="#C6C62C" x1="81.216" x2="79.233" y1="23.475" y2="20.261499999999998"/>
                <line class="hi" stroke="#FF0D0D" x1="77.25" x2="79.233" y1="17.048" y2="20.261499999999998"/>
                <line class="hi" stroke="#C6C62C" x1="83.291" x2="81.30799999999999" y1="22.195" y2="18.9815"/>
                <line class="hi" stroke="#FF0D0D" x1="79.325" x2="81.30799999999999" y1="15.768" y2="18.9815"/>
            </g>
                  
            <g class="bond" id="mol1bnd4">
                        
                <line x1="81.85" x2="74.024" y1="28.289" y2="31.4"/>
                        
                <line x1="80.949" x2="73.123" y1="26.023" y2="29.134"/>
                      
                <line class="hi" stroke="#C6C62C" x1="81.85" x2="77.937" y1="28.289" y2="29.8445"/>
                <line class="hi" stroke="#FF0D0D" x1="74.024" x2="77.937" y1="31.4" y2="29.8445"/>
                <line class="hi" stroke="#C6C62C" x1="80.949" x2="77.036" y1="26.023" y2="27.5785"/>
                <line class="hi" stroke="#FF0D0D" x1="73.123" x2="77.036" y1="29.134" y2="27.5785"/>
            </g>
                  
            <line class="bond" id="mol1bnd5" x1="85.03" x2="87.311" y1="29.921" y2="40.957"/>
                  
            <line class="bond" id="mol1bnd6" x1="87.311" x2="75.929" y1="40.957" y2="51.09"/>
                  
            <line class="bond" id="mol1bnd7" x1="75.929" x2="79.014" y1="51.09" y2="66.015"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="79.014" x2="67.544" y1="66.015" y2="76.273"/>
                        
                <line x1="79.584" x2="70.233" y1="68.776" y2="77.14"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="67.544" x2="70.82" y1="76.273" y2="91.128"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="70.82" x2="85.373" y1="91.128" y2="95.983"/>
                        
                <line x1="72.903" x2="84.785" y1="89.253" y2="93.216"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="85.373" x2="96.649" y1="95.983" y2="85.662"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="96.649" x2="93.47" y1="85.662" y2="70.839"/>
                        
                <line x1="93.972" x2="91.378" y1="84.807" y2="72.711"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="79.014" x2="93.47" y1="66.015" y2="70.839"/>
                  
            <line class="bond" id="mol1bnd14" x1="85.373" x2="85.277" y1="95.983" y2="107.267"/>
                  
            <line class="bond" id="mol1bnd15" x1="81.972" x2="70.784" y1="112.178" y2="115.804"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="61.87" x2="70.784" y1="103.49" y2="115.804"/>
                        
                <line x1="64.88" x2="71.719" y1="103.49" y2="112.937"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="70.82" x2="61.87" y1="91.128" y2="103.49"/>
                  
            <line class="bond" id="mol1bnd18" x1="61.87" x2="46.63" y1="103.49" y2="103.49"/>
                  
            <line class="bond" id="mol1bnd19" x1="46.63" x2="39.01" y1="103.49" y2="90.282"/>
                  
            <line class="bond" id="mol1bnd20" x1="39.01" x2="23.77" y1="90.282" y2="90.282"/>
                  
            <line class="bond" id="mol1bnd21" x1="23.77" x2="18.263" y1="90.282" y2="99.828"/>
                  
            <line class="bond" id="mol1bnd22" x1="18.263" x2="23.77" y1="107.153" y2="116.698"/>
                  
            <line class="bond" id="mol1bnd23" x1="23.77" x2="39.01" y1="116.698" y2="116.698"/>
                  
            <line class="bond" id="mol1bnd24" x1="46.63" x2="39.01" y1="103.49" y2="116.698"/>
                  
            <line class="bond" id="mol1bnd25" x1="12.809" x2=".91" y1="103.49" y2="103.49"/>
                  
            <g class="atom" id="mol1atm2">
                        
                <path d="M97.55 18.348h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.715l2.607 4.055h.03q-.006 -.108 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.578v4.9z" stroke="none"/>
                        
                <path d="M101.856 18.348h-.619v-2.286h-2.512v2.286h-.614v-4.9h.614v2.072h2.512v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M85.771 27.169q.0 .649 -.476 1.018q-.47 .363 -1.268 .363q-.417 .0 -.768 -.065q-.345 -.06 -.577 -.173v-.589q.244 .113 .607 .202q.369 .089 .762 .089q.547 .0 .827 -.214q.28 -.214 .28 -.577q.0 -.238 -.107 -.399q-.101 -.167 -.351 -.31q-.25 -.143 -.697 -.297q-.625 -.227 -.946 -.554q-.316 -.333 -.316 -.899q.0 -.393 .197 -.667q.202 -.28 .553 -.428q.357 -.155 .816 -.155q.405 -.0 .738 .077q.339 .072 .613 .197l-.196 .53q-.25 -.114 -.548 -.185q-.298 -.077 -.625 -.077q-.458 -.0 -.691 .196q-.232 .196 -.232 .518q.0 .244 .101 .411q.108 .166 .34 .297q.232 .125 .631 .28q.428 .155 .726 .339q.298 .179 .452 .435q.155 .25 .155 .637z" fill="#C6C62C" id="mol1atm3" stroke="none"/>
                  
            <path class="atom" d="M78.482 13.06q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .31 .756 .875q.256 .566 .256 1.328zM74.619 13.06q-.0 .922 .387 1.458q.393 .53 1.22 .53q.839 .0 1.22 -.53q.387 -.536 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" fill="#FF0D0D" id="mol1atm4" stroke="none"/>
                  
            <path class="atom" d="M72.324 31.659q-.0 .756 -.256 1.327q-.256 .566 -.757 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.501 .31 .757 .875q.256 .566 .256 1.328zM68.46 31.659q-.0 .922 .387 1.458q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" fill="#FF0D0D" id="mol1atm5" stroke="none"/>
                  
            <g class="atom" id="mol1atm14">
                        
                <path d="M87.185 113.567h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .357 .023 .732v2.739h-.565v-4.9h.714l2.608 4.054h.029q-.006 -.107 -.017 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" stroke="none"/>
                        
                <path d="M91.491 113.567h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M18.091 105.94h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" id="mol1atm20" stroke="none"/>
                
            <line class="hi" id="mol1bnd1" stroke="#3050F8" x1="94.819" x2="93.67150000000001" y1="12.077" y2="6.5255"/>
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="92.622" x2="89.6805" y1="18.557" y2="21.176000000000002"/>
            <line class="hi" id="mol1bnd2" stroke="#C6C62C" x1="86.739" x2="89.6805" y1="23.795" y2="21.176000000000002"/>
            <line class="hi" id="mol1bnd5" stroke="#C6C62C" x1="85.03" x2="86.1705" y1="29.921" y2="35.439"/>
            <line class="hi" id="mol1bnd14" stroke="#3050F8" x1="85.277" x2="85.325" y1="107.267" y2="101.625"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="81.972" x2="76.378" y1="112.178" y2="113.991"/>
            <line class="hi" id="mol1bnd21" stroke="#3050F8" x1="18.263" x2="21.0165" y1="99.828" y2="95.055"/>
            <line class="hi" id="mol1bnd22" stroke="#3050F8" x1="18.263" x2="21.0165" y1="107.153" y2="111.9255"/>
            <line class="hi" id="mol1bnd25" stroke="#3050F8" x1="12.809" x2="6.8595" y1="103.49" y2="103.49"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Title":"Naratriptan","UNII":"QX3KXL1ZA2","Wikidata":"Q421315","Wikipedia":"Naratriptan","XLogP":2}